ReviewInternational journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists2020
Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer.
Review in International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 160 citations in OpenAlex.
- A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Current status and targeted therapies in endometrial cancer: Molecular classification-driven treatment strategies (Review).Oncology letters · 2026Review
- Molecular classification-driven stage migration and prognostic risk stratification in endometrial cancers: FIGO 2023 vs FIGO 2009.Virchows Archiv : an international journal of pathology · 2026Article
- Advances in endometrial cancer screening: a comprehensive review of current methods and emerging technologies.International journal of clinical oncology · 2026Review
- Unraveling heterogeneity in LUAD via multi-omics integration: molecular classification and therapeutic implications.Discover oncology · 2026Article
- AXL inhibition improves the therapeutic efficacy of trastuzumab in high-risk endometrial cancer.Gynecologic oncology · 2026Article
- Histopathology Images-Based Deep Learning Prediction of Histological Types in Endometrial Cancer.Cancer medicine · 2026Article
- Research advancements regarding the relationship between FBXO2 and malignant tumors (Review).Molecular medicine reports · 2025Review
- Exploring the role of circular RNAs in endometrial cancer progression and chemoresistance: Implications for targeted therapies.European journal of medical research · 2025Review
- A New Direction in Endometrial Cancer Therapy-PD-1 and PD-L1 Immune Checkpoint Inhibitors-Where Will It Take Us?Journal of clinical medicine · 2025Review
- From Semantic Modeling to Precision Radiotherapy: An AI Framework Linking Radiobiology, Oncology, and Public Health Integration.Biomedicines · 2025Review
- Clinicopathological Analysis of a Group of Patients Diagnosed with Endometrial Cancer and Mutation in the Tp53 Gene-Single-Center Study.Journal of clinical medicine · 2025Article
- Clinical and Histopathological Correlates of Endometrial Proliferative Lesions in Perimenopausal Women: A Retrospective Study with Internal Validation of a Risk Model.Clinics and practice · 2025Article
- Integrating Multi-Omics in Endometrial Cancer: From Molecular Insights to Clinical Applications.Cells · 2025Review
- PDS5B positively regulates PTEN by binding to YTHDC1 to inhibit the malignant progression of endometrial carcinoma.Discover oncology · 2025Article
- Exploring the Relationship Between Adipocytokines and Endometrial Cancer: Identifying Correlations With Clinico-Pathological Prognostic Factors.Cancer medicine · 2025Article
- Carcinosarcoma of the Endometrium-Pathology, Molecular Landscape and Novel Therapeutic Approaches.Medicina (Kaunas, Lithuania) · 2025Review
- ZNF432 suppresses endometrial cancer progression by promoting UPF1 ubiquitination and inducing apoptosis.Discover oncology · 2025Article
- Unconventional success: Achieving long-term remission with pembrolizumab in recurrent high-grade endometrial carcinosarcoma.Gynecologic oncology reports · 2025Article
- Mechanism of miR-200b-3p-induced FOSL2 inhibition of endometrial cancer cell proliferation and metastasis.Scientific reports · 2025Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Recent advances in molecular studies, especially genome-wide analyses, have revealed the landscape of genomic alterations present in endometrial carcinomas, and have provided valuable insight into the pathogenesis of this disease. The current challenges are in developing a molecular-morphologic classification system to enhance traditional pathologic diagnosis and in determining the optimal approach to using this new information to guide clinical management. Molecular assays may be particularly beneficial in allowing the earlier detection of endometrial cancer or precursor lesions and in guiding personalized treatment approaches. In this review, we describe the current molecular landscape of endometrial cancers, efforts underway to incorporate molecular alterations into the current classification systems, and the development of diagnostic tools for the early detection of endometrial cancer. Finally, we present opportunities for using these data to tailor therapeutic strategies. A comprehensive understanding of the molecular alterations responsible for the origination, relapse, and resistance patterns of this disease will ultimately improve outcomes for patients with endometrial cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.